Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients - Scorecard - MDSpire
Advertisement
Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients
Clinical Scorecard: Creation of a nomogram for predicting metastatic prostate cancer and evaluation of NCCN, AUA, and EAU guidelines for bone imaging in affected patients
At a Glance
Category
Detail
Condition
Prostate cancer with risk of distant metastasis
Key Mechanisms
Metastasis primarily to bone; risk factors include PSA level, tumor stage, Gleason score, and biopsy core involvement
Target Population
Men diagnosed with prostate adenocarcinoma, particularly those at risk for metastatic disease
Care Setting
Oncology and urology clinical settings involving diagnosis and staging of prostate cancer
Key Highlights
Metastasis-free survival is a strong surrogate for overall survival in prostate cancer patients.
Bone is the major site of prostate cancer metastasis; guidelines recommend bone imaging selectively based on risk stratification.
Nomograms were developed using SEER data to predict distant and bone-only metastasis, aiding clinical decision-making.
Guideline-Based Recommendations
Diagnosis
NCCN recommends bone imaging if clinical T2b-c with PSA > 10 ng/ml, T3/T4 stage, PSA > 20 ng/ml, Gleason grade group ≥ 4, or primary Gleason pattern 5.
AUA recommends bone imaging for patients beyond unfavorable intermediate-risk group defined by Gleason grade and PSA/stage criteria.
EAU recommends bone imaging for intermediate-risk disease with Gleason grade group ≥ 3, high-risk disease, or locally advanced disease.
Management
Patients with unfavorable characteristics but no metastasis may benefit from additional follow-up or aggressive treatment to prevent metastasis.
Monitoring & Follow-up
Bone imaging is indicated for patients with symptoms consistent with bone metastases (consensus across guidelines).
Risks
Over-imaging low-risk patients is discouraged; guidelines agree on omitting bone imaging in low-risk prostate cancer.
Patient & Prescribing Data
Prostate adenocarcinoma patients with complete clinical and pathological data from SEER database (2010–2015).
Nomograms based on clinical variables (age, race, PSA, T and N stage, biopsy cores, Gleason score) can predict metastasis risk and guide imaging and treatment decisions.
Clinical Best Practices
Use routinely available clinical and pathological variables to stratify metastatic risk at diagnosis.
Apply validated nomograms to estimate individual risk of distant and bone-only metastasis.
Follow established guideline criteria to determine the need for bone imaging, avoiding unnecessary scans in low-risk patients.
Consider additional follow-up or aggressive treatment in patients with unfavorable features even if metastasis is not present.
With its combination of UWF imaging, OCT integration, and intelligent review tools, the MonacoPro represents the next step in comprehensive retinal evaluation. By improving image quality, enhancing diagnostic confidence, and streamlining workflow, the system supports clinicians in delivering more efficient, informed, and patient-centered care.
